US Patent

US8741327 — Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant

Method of Use · Assigned to University of Pennsylvania Penn · Expires 2027-11-12 · 1y remaining

Vulnerability score 66/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of maintaining therapeutic levels of a drug, specifically risperidone, in a subject using a PLA:PLGA implant.

USPTO Abstract

The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-543 — Risperdal
U-543 — Risperdal
U-543 — Risperdal
U-543 — Risperdal
U-543 — Risperdal
U-543 — Risperdal
U-543 — Risperdal

Patent Metadata

Patent number
US8741327
Jurisdiction
US
Classification
Method of Use
Expires
2027-11-12
Drug substance claim
No
Drug product claim
Yes
Assignee
University of Pennsylvania Penn
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.